Array Rises On Binimetinib Data, 2016 Regulatory Submissions
This article was originally published in Scrip
Executive Summary
Array Biopharma gained 20.6% to close at $4.62 per share on Dec. 16 after the company said it will seek regulatory approvals for binimetinib based on results from the Phase III NEMO clinical trials, which showed the MEK inhibitor nearly doubled median progression-free survival (PFS) for NRAS-mutant melanoma patients to 2.8 months versus 1.5 months for dacarbazine (p<>
You may also be interested in...
Array BioPharma’s Post-Approval Business Strategy Stymied
Following a meeting with the US FDA, Array BioPharma has withdrawn the NDA for its MEK inhibitor binimetinib because of insufficient evidence of clinical benefit in a tough-to-treat subgroup of melanoma patients, that may lead to a rethink of its commercialization strategy.
Array Rises As COLUMBUS Clears Phase III Melanoma Hurdle
Shares in Array Biopharma shot up by more than 80% on the release of top-line Phase III data from its COLUMBUS study of encorafenib and binimetinib, but more details are needed to gauge how the combination may fare against Novartis and Roche’s more established combos, and the newer IO therapies.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.